The US Food and Drug Administration approved a supplemental biologics licence application on 13 July 2026 allowing the LEQEMBI IQLIK autoinjector (lecanemab-irmb) to be used to start treatment for early Alzheimer's disease, not only to continue it. Eisai and Biogen, which co-commercialise the drug, state that the initiation presentation is expected in the United States in late August 2026 and will be supplied through a specialty pharmacy. The FDA-approved prescribing information, revised in July 2026, sets the initiation dosage at 500 mg once a week, given as two 250 mg subcutaneous injections, each delivered in approximately 15 seconds; maintenance dosing remains 360 mg once a week after 18 months of intravenous or subcutaneous treatment. Until this approval, an anti-amyloid antibody could be started in the United States only as an intravenous infusion.

The monitoring requirements around the injection are unchanged. The boxed warning on amyloid related imaging abnormalities (ARIA), swelling and small bleeds visible on scans, still stands, and the labelling states that ARIA can be fatal. A recent baseline brain MRI is required before treatment, with further MRIs after 1, 2, 3 and 6 months of treatment; for the subcutaneous route the one month scan falls before the fifth weekly dose. The label also directs that therapy be initiated under the guidance and supervision of a health care provider, and that a patient or caregiver may inject only after the provider has given direct guidance for at least two consecutive subcutaneous doses and has judged self-administration appropriate, with the ability periodically reassessed. Testing for ApoE e4 status before starting is recommended, because homozygotes have a higher incidence of ARIA.

The approval rests on matched drug exposure rather than a fresh outcome trial. The FDA said the subcutaneous formulation was not evaluated separately in large clinical outcome trials, and that its effectiveness is supported by the intravenous formulation's trial results together with evidence of equivalent exposure in the body and similar reductions in amyloid plaques, according to the agency's statement reported on 14 July 2026. The prescribing information records that the safety of once weekly subcutaneous dosing was evaluated in open-label studies in 424 patients, of whom 72 had not previously received lecanemab; 273 received 500 mg subcutaneously as treatment continuation and 49 received 360 mg. Injection reactions are described as mostly local, including redness, swelling, rash, pain and bruising.

The risk figures that drive the monitoring come from the intravenous programme. In the 18 month placebo-controlled trial of 1,795 participants, ARIA-E was seen in 13 percent of those on lecanemab against 2 percent on placebo, and ARIA-H in 14 percent against 8 percent. No published trial has compared starting at home with starting in an infusion suite, so there is no evidence yet on whether scans are obtained on schedule, or symptoms reported as quickly, when the first doses are given at a kitchen table rather than a clinic.